<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="589d789c-2fbd-40ee-bbe4-8906afa2062d"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use SUFENTANIL CITRATE INJECTION, safely and effectively. See full prescribing information for SUFENTANIL CITRATE INJECTION.<br/>
      <br/>Sufentanil Citrate Injection, for intravenous and epidural use, CII<br/>Initial U.S. Approval: 1984</title>
   <effectiveTime value="20250107"/>
   <setId root="20293943-46ff-4345-1aa4-929b4e017a25"/>
   <versionNumber value="30"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="141588017" root="1.3.6.1.4.1.519.1"/>
            <name>Hospira, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="093132819" root="1.3.6.1.4.1.519.1"/>
                        <name>Hospira, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-3382" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-3382" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-3382" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-3382" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="827731089" root="1.3.6.1.4.1.519.1"/>
                        <name>Hospira, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-3382" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="81cddaa5-4101-49a3-93c8-54d5388b12da"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20230717"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0409-3382" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Sufentanil Citrate</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>SUFENTANIL CITRATE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="ug" value="50"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="S9ZFX8403R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUFENTANIL CITRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="AFE2YW0IIZ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SUFENTANIL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0409-3382-11" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0409-3382-21" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20050726"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="2"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0409-3382-12" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0409-3382-22" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20050808"/>
                                          <high value="20220201"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0409-3382-15" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0409-3382-25" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20051025"/>
                                          <high value="20220201"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA074534" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20050726"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="EPIDURAL"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_E9CFB322-9E15-4026-94E0-2974DE0AB8BA">
               <id root="9fd9b09f-ed52-479e-b64f-77ca9cf1732d"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph/>
                        <table styleCode="Noautorules" width="100%">
                           <col width="91%"/>
                           <col width="9%"/>
                           <tbody>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Boxed Warning</paragraph>
                                 </td>
                                 <td align="right" valign="middle">
                                    <paragraph>12/2023‎</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Warnings and Precautions (<linkHtml href="#ID_2023a8f1-4f67-4fe0-974f-1f2a311e5855">5.7</linkHtml>)</paragraph>
                                 </td>
                                 <td align="right" valign="middle">
                                    <paragraph>12/2023‎</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="699c42c5-477e-43a7-bae8-e9bc88086770"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
               <title>WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF SUFENTANIL CITRATE ‎INJECTION </title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">
                        <content styleCode="bold">
                           <content styleCode="underline">Addiction, Abuse, and Misuse</content>
                        </content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="xmChange">Because the use of Sufentanil Citrate Injection exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions <content styleCode="italics">‎[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]‎</content>
                        </content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="xmChange">
                        <content styleCode="bold">
                           <content styleCode="underline">Life-Threatening Respiratory Depression</content>
                        </content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="xmChange">
                        <content styleCode="bold">Serious, life-threatening, or fatal respiratory depression may occur with use of ‎Sufentanil Citrate Injection, ‎especially during initiation or following a dosage ‎increase. To reduce the risk of respiratory depression, proper dosing ‎and ‎titration of Sufentanil Citrate Injection are essential <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and ‎Precautions (5.2)</linkHtml>]</content>.‎</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="xmChange">
                        <content styleCode="bold">
                           <content styleCode="underline">Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants</content>
                        </content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="xmChange">
                        <content styleCode="bold">‎‎Concomitant use of opioids with benzodiazepines or other central nervous ‎system (CNS) depressants, including ‎alcohol, may result in profound sedation, ‎respiratory depression, coma, and death. Reserve concomitant prescribing of ‎‎Sufentanil Citrate Injection and benzodiazepines or other CNS depressants for ‎use in patients for whom ‎alternative treatment options are inadequate <content styleCode="italics">[see ‎<linkHtml href="#ID_6ba564bf-915e-4370-a8fa-52b7dec44b36">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.‎</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="xmChange">
                        <content styleCode="bold">
                           <content styleCode="underline">Cytochrome P450 3A4 Interaction</content>
                        </content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="xmChange">
                        <content styleCode="bold">The concomitant use of Sufentanil Citrate Injection with all cytochrome P450 ‎‎3A4 inhibitors may result in an ‎increase in sufentanil plasma concentrations, ‎which could increase or prolong adverse reactions and may cause ‎potentially ‎fatal respiratory depression. In addition, discontinuation of a concomitantly used ‎cytochrome P450 3A4 ‎inducer may result in an increase in sufentanil plasma ‎concentration. Monitor patients receiving Sufentanil Citrate Injection and any ‎CYP3A4 inhibitor or inducer <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.4)</linkHtml>, <linkHtml href="#S7">Drug ‎Interactions (7)</linkHtml>, ‎<linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>
                           <content styleCode="italics">‎</content>
                        </content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF SUFENTANIL CITRATE ‎INJECTION</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">Sufentanil Citrate Injection exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions <content styleCode="italics">
                                    <linkHtml href="#S5.1">(5.1)</linkHtml>
                                 </content>.</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">Serious, life-threatening, or fatal respiratory depression may occur with use of ‎Sufentanil Citrate Injection, ‎especially during initiation or following a dosage ‎increase. To reduce the risk of respiratory depression, proper dosing ‎and ‎titration of Sufentanil Citrate Injection are essential <content styleCode="italics">
                                    <linkHtml href="#S5.2">(5.2)</linkHtml>
                                 </content>.</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">Concomitant use of opioids with benzodiazepines or other central nervous ‎system (CNS) depressants, including ‎alcohol, may result in profound sedation, ‎respiratory depression, coma, and death. Reserve concomitant prescribing for ‎use in patients for whom ‎alternative treatment options are inadequate </content>
                              <content styleCode="bold">
                                 <content styleCode="italics">
                                    <linkHtml href="#ID_6ba564bf-915e-4370-a8fa-52b7dec44b36">(5.3, </linkHtml>
                                 </content>
                              </content>
                              <content styleCode="bold">
                                 <content styleCode="italics">
                                    <linkHtml href="#S7">7)</linkHtml>
                                 </content>.</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="bold">Concomitant use with CYP3A4 inhibitors (or discontinuation of ‎CYP3A4 inducers) can result in a fatal overdose of sufentanil </content>
                              <content styleCode="bold">
                                 <content styleCode="italics">
                                    <linkHtml href="#S5.3">(5.4, </linkHtml>
                                 </content>
                              </content>
                              <content styleCode="bold">
                                 <content styleCode="italics">
                                    <linkHtml href="#S7">7</linkHtml>, ‎<linkHtml href="#S12.3">12.3)</linkHtml>
                                 </content>‎.</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="522f949b-3201-4269-8ce1-250976bed8f3"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Sufentanil Citrate Injection is indicated for intravenous administration in adults and pediatric patients:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>as an analgesic adjunct in the maintenance of balanced general anesthesia in patients who are intubated and ventilated.</item>
                     <item>
                        <caption>•</caption>as a primary anesthetic agent for the induction and maintenance of anesthesia with 100% oxygen in patients undergoing major surgical procedures, in patients who are intubated and ventilated, such as cardiovascular surgery or neurosurgical procedures in the sitting position, to provide favorable myocardial and cerebral oxygen balance or when extended postoperative ventilation is anticipated.</item>
                  </list>
                  <paragraph>Sufentanil Citrate Injection is indicated for epidural administration:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>as an analgesic combined with low dose (usually 12.5 mg per administration) bupivacaine usually during labor and vaginal delivery.</item>
                  </list>
               </text>
               <effectiveTime value="20230717"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Sufentanil Citrate Injection is an opioid agonist indicated (<linkHtml href="#S1">1</linkHtml>): </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>as an analgesic adjunct in the maintenance of balanced general anesthesia in patients who are intubated and ventilated.</item>
                           <item>
                              <caption>•</caption>as a primary anesthetic agent for the induction and maintenance of anesthesia with 100% oxygen in patients undergoing major surgical procedures, in patients who are intubated and ventilated, such as cardiovascular surgery or neurosurgical procedures in the sitting position, to provide favorable myocardial and cerebral oxygen balance or when extended postoperative ventilation is anticipated.</item>
                           <item>
                              <caption>•</caption>for epidural administration as an analgesic combined with low dose (usually 12.5 mg per administration) bupivacaine usually during labor and vaginal delivery.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="18a6f246-8090-40a6-95be-ecee445212f5"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Sufentanil Citrate Injection should be administered only by persons specifically trained in the use of intravenous anesthetics and management of the respiratory effects of potent opioids.</item>
                           <item>
                              <caption>•</caption>Ensure that an opioid antagonist, resuscitative and intubation equipment, and oxygen are readily available. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Individualize dosing based on factors such as age, body weight, physical status, underlying pathological condition, use of other drugs, type of anesthesia to be used, and the surgical procedure involved. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Initiate analgesic treatment with 1 to 2 mcg/kg intravenously. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Initiate epidural injection for labor and delivery at 10 to 15 mcg of Sufentanil administered with 10 mL bupivacaine 0.125% with or without epinephrine. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="7d6ea201-03be-450f-85ff-a12ecba9520b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Dosage and Administration Instructions</title>
                     <text>
                        <paragraph>Sufentanil Citrate Injection should be administered only by persons specifically trained in the use of intravenous or epidural anesthetics and management of the respiratory effects of potent opioids.</paragraph>
                        <paragraph>In patients administered high doses of Sufentanil Citrate Injection, it is essential that qualified personnel and adequate facilities are available for the management of postoperative respiratory depression.</paragraph>
                        <paragraph>For purposes of administering small volumes of Sufentanil Citrate Injection accurately, the use of a tuberculin syringe or equivalent is recommended.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Ensure that an opioid antagonist, resuscitative and intubation equipment, and oxygen are readily available.</item>
                           <item>
                              <caption>•</caption>Individualize dosage based on factors such as age, body weight, physical status, underlying pathological condition, use of other drugs, type of anesthesia to be used, and the surgical procedure involved.</item>
                           <item>
                              <caption>•</caption>Monitor vital signs regularly.</item>
                           <item>
                              <caption>•</caption>The selection of preanesthetic medications should be based upon the needs of the individual patient. </item>
                           <item>
                              <caption>•</caption>The neuromuscular blocking agent selected should be compatible with the patient's condition, taking into account the hemodynamic effects of a particular muscle relaxant and the degree of skeletal muscle relaxation required.</item>
                        </list>
                        <paragraph>As with other potent opioids, the respiratory depressant effect of sufentanil may persist longer than the measured analgesic effect. The total dose of all opioid agonists administered should be considered by the practitioner before ordering opioid analgesics during recovery from anesthesia.</paragraph>
                        <paragraph>If Sufentanil Citrate Injection is administered with a CNS depressant, become familiar with the properties of each drug, particularly each product's duration of action. In addition, when such a combination is used, fluids and other countermeasures to manage hypotension should be available <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_6ba564bf-915e-4370-a8fa-52b7dec44b36">Warnings and Precautions (5.3)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="0087cdbb-9787-4a2c-ad58-fdc6dd13fd25"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Intravenous use</title>
                     <text>
                        <paragraph>Sufentanil Citrate may be administered intravenously by slow injection or infusion.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                     <component>
                        <section ID="ID_b037e291-d81e-4a97-b790-27640bc27932">
                           <id root="af858f5d-522a-4afc-9478-35e9dd00ea3b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adjunct to general anesthesia:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Doses of up to 8 mcg/kg (see <linkHtml href="#_RefTable1">Table 1</linkHtml>)</item>
                                 <item>
                                    <caption>•</caption>Total Dosage Requirements of 1 mcg/kg/hr or less are recommended</item>
                                 <item>
                                    <caption>•</caption>Dosage should be individualized and adjusted to remaining operative time anticipated.</item>
                              </list>
                              <table ID="_RefTable1" width="100%">
                                 <caption>Table 1: Adult Dosage Range Chart, Analgesic Component To General Anesthesia, Intravenous Use</caption>
                                 <col width="50%"/>
                                 <col width="50%"/>
                                 <thead>
                                    <tr>
                                       <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <content styleCode="bold">Total dosage</content>
                                       </th>
                                       <th align="left" styleCode="Rrule Botrule Toprule " valign="top">
                                          <content styleCode="bold">Maintenance dosage</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td align="center" colspan="2" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Duration of anesthesia 1 to 2 hours</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Incremental or Infusion: 1 to 2 mcg/kg</content>
                                             <br/>Approximately 75% or more of total sufentanil dosage may be administered prior to intubation by either slow injection or infusion titrated to individual patient response.<br/>
                                             <br/>Dosages in this range are generally administered with nitrous oxide/oxygen in patients undergoing general surgery in which endotracheal intubation and mechanical ventilation are required.</paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Incremental: 10 to 25 mcg (0.2 to 0.5 mL) </content>may be administered in increments as needed when movement and/or changes in vital signs indicate surgical stress or lightening of analgesia. Supplemental dosages should be individualized and adjusted to remaining operative time anticipated.<br/>
                                             <br/>
                                             <content styleCode="bold">Infusion: </content>Intermittent or continuous infusion as needed in response to signs of lightening of analgesia.<br/>
                                             <br/>In absence of signs of lightening of analgesia, infusion rates should always be adjusted downward until there is some response to surgical stimulation.<br/>
                                             <br/>Maintenance infusion rates should be adjusted based upon the induction dose of sufentanil so that the total dose does not exceed 1 mcg/kg/hr of expected surgical time.</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Duration of anesthesia 2 to 8 hours</content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Incremental or Infusion: 2 to 8 mcg/kg</content>
                                             <br/>Approximately 75% or less of the total calculated sufentanil dosage may be administered by slow injection or infusion prior to intubation, titrated to individual patient response.<br/>
                                             <br/>Dosages in this range are generally administered with nitrous oxide/oxygen in patients undergoing more complicated major surgical procedures in which endotracheal intubation and mechanical ventilation are required.<br/>
                                             <br/>At dosages in this range, sufentanil has been shown to provide some attenuation of sympathetic reflex activity in response to surgical stimuli, provide hemodynamic stability, and provide relatively rapid recovery.</paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Incremental: 10 to 50 mcg (0.2 to 1 mL) </content>may be administered in increments as needed when movement and/or changes in vital signs indicate surgical stress or lightening of analgesia. Supplemental dosages should be individualized and adjusted to the remaining operative time anticipated.<br/>
                                             <br/>
                                             <content styleCode="bold">Infusion: </content>Intermittent or continuous infusion as needed in response to signs of lightening of analgesia.<br/>
                                             <br/>In the absence of signs of lightening of analgesia, infusion rates should always be adjusted downward until there is some response to surgical stimulation.<br/>
                                             <br/>Maintenance infusion rates should be adjusted based upon the induction dose of sufentanil so that the total dose does not exceed 1 mcg/kg/hr of expected surgical time.</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20231218"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_ccfbb190-82c7-482f-83d6-ce14c5eafeec">
                           <id root="79fc2184-02a9-42c7-9139-71c0f791a4f1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Induction And Maintenance Of Anesthesia</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>As the primary anesthetic agent: doses ≥8 mcg/kg (see <linkHtml href="#_RefTable2">Dosage Range Chart, Table 2</linkHtml>).</item>
                                 <item>
                                    <caption>•</caption>Dosage should be titrated to individual patient response</item>
                                 <item>
                                    <caption>•</caption>In children less than 12 years of age undergoing cardiovascular surgery: 10 to 25 mcg/kg administered with 100% oxygen<list listType="unordered">
                                       <item>
                                          <caption>o</caption>Supplemental dosages of up to 25 to 50 mcg are recommended for maintenance, based on response to initial dose and as determined by changes in vital signs indicating surgical stress or lightening of anesthesia.</item>
                                    </list>
                                 </item>
                              </list>
                              <table ID="_RefTable2" width="100%">
                                 <caption>Table 2: Dosage Range Chart, Induction and Maintenance of Anesthesia, Intravenous Use</caption>
                                 <col width="50%"/>
                                 <col width="50%"/>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Incremental or Infusion: 8 to 30 mcg/kg</content>
                                             <br/>Generally administered as a slow injection, as an infusion, or as an injection followed by an infusion.<br/>
                                             <br/>Sufentanil with 100% oxygen and a muscle relaxant has been found to produce sleep at dosages ≥8 mcg/kg and to maintain a deep level of anesthesia without the use of additional anesthetic agents. The addition of N<sub>2</sub>O to these dosages will reduce systolic blood pressure. At dosages in this range of up to 25 mcg/kg, catecholamine release is attenuated.<br/>
                                             <br/>Dosages of 25 to 30 mcg/kg have been shown to block sympathetic response including catecholamine release.<br/>
                                             <br/>High doses are indicated in patients undergoing major surgical procedures, in which endotracheal intubation and mechanical ventilation are required, such as cardiovascular surgery and neurosurgery in the sitting position with maintenance of favorable myocardial and cerebral oxygen balance.<br/>
                                             <br/>Postoperative observation is essential and postoperative mechanical ventilation may be required at the higher dosage range due to extended postoperative respiratory depression.</paragraph>
                                       </td>
                                       <td styleCode="Rrule Botrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Incremental: </content>Depending on the initial dose, maintenance doses of 0.5 to 10 mcg/kg may be administered by slow injection in anticipation of surgical stress such as incision, sternotomy or cardiopulmonary bypass.<br/>
                                             <br/>
                                             <content styleCode="bold">Infusion: </content>Sufentanil citrate may be administered by continuous or intermittent infusion as needed in response to signs of lightening of anesthesia.<br/>
                                             <br/>In the absence of lightening of anesthesia, infusion rates should always be adjusted downward until there is some response to surgical stimulation.<br/>
                                             <br/>The maintenance infusion rate for sufentanil should be based upon the induction dose so that the total dose for the procedure does not exceed 30 mcg/kg.</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250101"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="ae0a463b-67cd-48d4-9482-6dfd1f2c3eb4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Epidural Use in Labor and Delivery</title>
                     <text>
                        <paragraph>Proper placement of the needle or catheter in the epidural space should be verified before sufentanil citrate is injected to assure that unintentional intravascular or intrathecal administration does not occur. Unintentional intravascular injection of sufentanil could result in a potentially serious overdose, including acute truncal muscular rigidity and apnea. Unintentional intrathecal injection of the full sufentanil, bupivacaine epidural doses and volume could produce effects of high spinal anesthesia including prolonged paralysis and delayed recovery.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Sufentanil should be administered by slow injection. Respiration should be closely monitored following each administration of an epidural injection of sufentanil.</item>
                           <item>
                              <caption>•</caption>If analgesia is inadequate, the placement and integrity of the catheter should be verified prior to the administration of any additional epidural medications.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250101"/>
                     <component>
                        <section ID="ID_7936ca6c-8769-4461-b209-6fa08d7069b2">
                           <id root="51624bca-a0a8-4582-8a47-9cfc43f50287"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dosage for Labor and Delivery</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>10 to 15 mcg administered with 10 mL bupivacaine 0.125% with or without epinephrine.</item>
                                 <item>
                                    <caption>•</caption>Sufentanil and bupivacaine should be mixed together before administration.</item>
                                 <item>
                                    <caption>•</caption>Doses can be repeated twice (for a total of three doses) at not less than one-hour intervals until delivery.</item>
                              </list>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="25f2130a-0cac-4bec-bf25-c4049ac7961f"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Sufentanil Citrate Injection, USP 50 mcg/mL (equivalent to 50 mcg/mL sufentanil base).</paragraph>
               </text>
               <effectiveTime value="20231218"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Solution for injection (sterile): eq. to 50 mcg/mL sufentanil base; 1 mL, 2 mL and 5 mL vials. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="de1ccd06-af03-4b58-8d45-37b63c376122"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Sufentanil Citrate Injection is contraindicated in patients with:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Hypersensitivity to sufentanil (e.g., anaphylaxis) <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20231218"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Hypersensitivity to sufentanil. (<linkHtml href="#S4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="ab2cd186-8557-4400-8784-b44354bf2fff"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or</content>
                              <br/>
                              <content styleCode="underline">Debilitated Patients</content>: Monitor closely, particularly during initiation and titration. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Risks of Skeletal Muscle Rigidity and Skeletal Muscle Movement</content>: Manage with neuromuscular blocking agent. See full prescribing information for more detail on managing these risks. (<linkHtml href="#S5.4">5.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Severe Cardiovascular Depression</content>: Monitor during dosage initiation and titration. (<linkHtml href="#S5.6">5.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Opioid-Induced Hyperalgesia and Allodynia</content>: Opioid-Induced ‎Hyperalgesia (OIH) occurs when an opioid analgesic ‎paradoxically causes an increase in pain, or an increase in ‎sensitivity to pain. If OIH is suspected, carefully consider appropriately ‎decreasing the dose of the current opioid analgesic, or ‎opioid rotation. (<linkHtml href="#ID_2023a8f1-4f67-4fe0-974f-1f2a311e5855">5.7</linkHtml>)‎</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Serotonin Syndrome</content>: Potentially life-threatening condition could result from concomitant serotonergic drug administration. Discontinue Sufentanil Citrate Injection if serotonin syndrome is suspected. (<linkHtml href="#S5.7">5.8</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, or Head Injury</content>: Monitor for sedation and respiratory depression. (<linkHtml href="#S5.9">5.10</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="5e6cb4bf-e259-45d3-90a1-3af18c56e8e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Addiction, Abuse, and Misuse</title>
                     <text>
                        <paragraph>Sufentanil Citrate Injection contains sufentanil, a Schedule II controlled substance. As an opioid, Sufentanil Citrate Injection exposes users to the risks of addiction, abuse, and misuse <content styleCode="italics">[see <linkHtml href="#S9">Drug Abuse and Dependence (9)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Opioids are sought for nonmedical use and are subject to diversion from ‎legitimate prescribed use. Consider these risks when handling Sufentanil Citrate Injection. Strategies to reduce these risks include proper product storage and control practices for a C-II drug. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="3921f2dd-cd75-4fd2-8e5f-a96b53830e03"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Life-Threatening Respiratory Depression</title>
                     <text>
                        <paragraph>Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Sufentanil Citrate Injection should be administered only by persons specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, including respiration and cardiac resuscitation of patients in the age group being treated. Such training must include the establishment and maintenance of a patent airway and assisted ventilation. Adequate facilities should be available for postoperative monitoring and ventilation of patients administered anesthetic doses of Sufentanil Citrate Injection. It is essential that these facilities be fully equipped to handle all degrees of respiratory depression. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status <content styleCode="italics">[see <linkHtml href="#S10">Overdosage (10)</linkHtml>]</content>. Carbon dioxide (CO<sub>2</sub>) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</paragraph>
                        <paragraph>As with other potent opioids, the respiratory depressant effect of Sufentanil Citrate Injection may persist longer than the measured analgesic effect. The total dose of all opioid agonists administered should be considered by the practitioner before ordering opioid analgesics during recovery from anesthesia.</paragraph>
                        <paragraph>Certain forms of conduction anesthesia, such as spinal anesthesia and some epidural anesthetics, can alter respiration by blocking intercostal nerves <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>].</content> Sufentanil Citrate Injection can also alter respiration. Therefore, when Sufentanil Citrate Injection is used to supplement these forms of anesthesia, the anesthetist should be familiar with the physiological alterations involved, and be prepared to manage them in the patients selected for these forms of anesthesia.</paragraph>
                        <paragraph>Patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of Sufentanil Citrate Injection. Elderly, cachectic, or debilitated patients may have altered pharmacokinetics or altered clearance compared to younger, healthier patients resulting in greater risk for respiratory depression.</paragraph>
                        <paragraph>Monitor such patients closely including vital signs, particularly when initiating and titrating Sufentanil Citrate Injection and when Sufentanil Citrate Injection is given concomitantly with other drugs that depress respiration. To reduce the risk of respiratory depression, proper dosing and titration of Sufentanil Citrate Injection are essential <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6ba564bf-915e-4370-a8fa-52b7dec44b36">
                     <id root="82475768-7f3f-454b-a850-88ba2f7945de"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants </title>
                     <text>
                        <paragraph>When benzodiazepines or other CNS depressants are used with Sufentanil Citrate Injection, pulmonary arterial pressure may be decreased. This fact should be considered by those who conduct diagnostic and surgical procedures where interpretation of pulmonary arterial pressure measurements might determine final management of the patient. When high dose or anesthetic dosages of Sufentanil Citrate Injection are employed, even relatively small dosages of diazepam may cause cardiovascular depression.</paragraph>
                        <paragraph>When Sufentanil Citrate Injection is used with CNS depressants, hypotension can occur. If it occurs, consider the possibility of hypovolemia and manage with appropriate parenteral fluid therapy. When operative conditions permit, consider repositioning the patient to improve venous return to the heart. Exercise care in moving and repositioning of patients because of the possibility of orthostatic hypotension. If volume expansion with fluids plus other countermeasures do not correct hypotension, consider administration of pressor agents other than epinephrine. Epinephrine may paradoxically decrease blood pressure in patients treated with a neuroleptic that blocks alpha adrenergic activity. </paragraph>
                        <paragraph>Profound sedation, respiratory depression, coma, and death may result from the concomitant use of Sufentanil Citrate Injection with benzodiazepines and/or other CNS depressants including alcohol (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids).</paragraph>
                        <paragraph>Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                        <paragraph>If the decision is made to manage postoperative pain with Sufentanil Citrate Injection concomitantly with a benzodiazepine or other CNS depressant, start dosing with the lowest effective dosage and titrate based on clinical response. Monitor patients closely for signs and symptoms of respiratory depression, sedation, and hypotension. Fluids or other measures to counter hypotension should be available <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="7c4142ff-c343-415d-a61e-e35f89a68f29"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Risks of Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers</title>
                     <text>
                        <paragraph>Concomitant use of Sufentanil Citrate Injection with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of sufentanil and prolong opioid adverse reactions, which may exacerbate fatal respiratory depression <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>, particularly when an inhibitor is added after a stable dose of Sufentanil Citrate Injection is achieved<content styleCode="italics">.</content> Similarly, discontinuation of a CYP3A4 inducer, such as rifampin, carbamazepine, and phenytoin, in Sufentanil Citrate Injection-treated patients may increase sufentanil plasma concentrations and prolong opioid adverse reactions. When using Sufentanil Citrate Injection with CYP3A4 inhibitors or discontinuing CYP3A4 inducers in Sufentanil Citrate Injection-treated patients, monitor patients closely at frequent intervals and consider dosage reduction of Sufentanil Citrate Injection <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Concomitant use of Sufentanil Citrate Injection with CYP3A4 inducers or discontinuation of an CYP3A4 inhibitor could result in lower than expected sufentanil plasma concentrations, decreased efficacy, or, possibly, lead to a withdrawal syndrome in a patient who had developed physical dependence to sufentanil. When using Sufentanil Citrate Injection with CYP3A4 inducers or discontinuing CYP3A4 inhibitors, monitor patients closely at frequent intervals and consider increasing the Sufentanil Citrate Injection dosage <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="20a06ddb-ed7b-423c-aa21-d537f3d8afd7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Risks of Muscle Rigidity and Skeletal Muscle Movement</title>
                     <text>
                        <paragraph>Intravenous administration or unintentional intravascular injection during epidural administration of Sufentanil Citrate Injection may cause muscle rigidity, particularly involving the muscles of respiration. The incidence and severity of muscle rigidity is dose related. These effects are related to the dose and speed of injection. Administration of sufentanil may produce muscular rigidity with a more rapid onset of action than that seen with fentanyl. Skeletal muscle rigidity also has been reported to occur or recur infrequently in the extended postoperative period usually following high dose administration. In addition, skeletal muscle movements of various groups in the extremities, neck, and external eye have been reported during induction of anesthesia with Sufentanil Citrate Injection; these reported movements have, on rare occasions, been strong enough to pose patient management problems.</paragraph>
                        <paragraph>The incidence of skeletal muscle rigidity can be reduced by: 1) administration of up to 1/4 of the full paralyzing dose of a non-depolarizing neuromuscular blocking agent just prior to administration of sufentanil at dosages of up to 8 mcg/kg, 2) administration of a full paralyzing dose of a neuromuscular blocking agent following loss of consciousness when sufentanil is used in anesthetic dosages (above 8 mcg/kg) titrated by slow intravenous infusion, or, 3) simultaneous administration of sufentanil and a full paralyzing dose of a neuromuscular blocking agent when sufentanil is used in rapidly administered anesthetic dosages (above 8 mcg/kg).</paragraph>
                        <paragraph>The neuromuscular blocking agents used should be compatible with the patient's cardiovascular status. The hemodynamic effects and degree of skeletal muscle relaxation required should be considered in the selection of a neuromuscular blocking agent. High doses of pancuronium may produce increases in heart rate during sufentanil-oxygen anesthesia. Bradycardia and hypotension have been reported with other muscle relaxants during sufentanil-oxygen anesthesia; this effect may be more pronounced in the presence of calcium channel and/or beta-blockers. Muscle relaxants with no clinically significant effect on heart rate (at recommended doses) would not counteract the vagotonic effect of sufentanil, therefore a lower heart rate would be expected. Rare reports of bradycardia associated with the concomitant use of succinylcholine and sufentanil have been reported.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="ddbad37a-a06d-4f14-ba45-7177dec75333"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Severe Cardiovascular Depression</title>
                     <text>
                        <paragraph>Sufentanil Citrate Injection may cause severe bradycardia, severe hypotension including orthostatic hypotension, and syncope. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].</content> In patients with circulatory shock, Sufentanil Citrate Injection may cause vasodilation that can further reduce cardiac output and blood pressure. Monitor these patients for signs of hypotension after initiating or titrating the dosage of Sufentanil Citrate Injection.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2023a8f1-4f67-4fe0-974f-1f2a311e5855">
                     <id root="5cee147b-d33d-40af-bd91-749ee95605c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Opioid-Induced Hyperalgesia and Allodynia </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic ‎paradoxically causes an increase in pain, or an increase in sensitivity to pain. ‎This condition differs from tolerance, which is the need for increasing doses of ‎opioids to maintain a defined effect <content styleCode="italics">[see <linkHtml href="#S9.3">Dependence (9.3)</linkHtml>]</content>. Symptoms of OIH ‎include (but may not be limited to) increased levels of pain upon opioid dosage ‎increase, decreased levels of pain upon opioid dosage decrease, or pain from ‎ordinarily non-painful stimuli (allodynia). These symptoms may suggest OIH only ‎if there is no evidence of underlying disease progression, opioid tolerance, ‎opioid withdrawal, or addictive behavior.‎</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Cases of OIH have been reported, both with short-term and longer-term use of ‎opioid analgesics. Though the mechanism of OIH is not fully understood, ‎multiple biochemical pathways have been implicated. Medical literature suggests ‎a strong biologic plausibility between opioid analgesics and OIH and allodynia. If ‎a patient is suspected to be experiencing OIH, carefully consider appropriately ‎decreasing the dose of the current opioid analgesic or opioid rotation (safely ‎switching the patient to a different opioid moiety) <content styleCode="italics">[see <linkHtml href="#S2">Dosage and ‎Administration (2)</linkHtml>, <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.‎</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="aa6569fa-c3fd-4993-9b63-94d41d9827a3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Serotonin Syndrome with Concomitant Use of Serotonergic Drugs</title>
                     <text>
                        <paragraph>Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of sufentanil with serotonergic drugs. Serotonergic drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonergic neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and drugs that impair metabolism of serotonin (including MAO inhibitors, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue) <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>. This may occur within the recommended dosage range.</paragraph>
                        <paragraph>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) and can be fatal. The onset of symptoms generally occurs within several hours to a few days of concomitant use, but may occur later than that. Discontinue Sufentanil Citrate Injection if serotonin syndrome is suspected.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="dfda11cf-8fbb-49fe-8179-947dd865ab33"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Risks due to Improper Epidural Injection</title>
                     <text>
                        <paragraph>Proper placement of the needle or catheter in the epidural space should be verified before sufentanil is injected to assure that unintentional intravascular or intrathecal administration does not occur. Unintentional intravascular injection of sufentanil could result in a potentially serious overdose, including acute truncal muscular rigidity and apnea. Unintentional intrathecal injection of the full sufentanil/bupivacaine epidural doses and volume could produce effects of high spinal anesthesia including prolonged paralysis and delayed recovery. If analgesia is inadequate, the placement and integrity of the catheter should be verified prior to the administration of any additional epidural medications. Sufentanil should be administered epidurally by slow injection.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="c384c117-c227-4a70-830d-3cca0134a739"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, or Head Injury</title>
                     <text>
                        <paragraph>In patients who may be susceptible to the intracranial effects of CO<sub>2</sub> retention (e.g., those with evidence of increased intracranial pressure or brain tumors), Sufentanil Citrate Injection may reduce respiratory drive, and the resultant CO<sub>2</sub> retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with Sufentanil Citrate Injection. Opioids may also obscure the clinical course in a patient with a head injury. </paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="f531e08b-177f-4639-9b1c-ae988c54cef4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Risks of Use in Patients with Gastrointestinal Conditions</title>
                     <text>
                        <paragraph>Sufentanil may cause spasm of the sphincter of Oddi. Opioids may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis for worsening symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.11">
                     <id root="1f5fe004-8264-4295-9d5e-bfef8b7cc300"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Increased Risk of Seizures in Patients with Seizure Disorders</title>
                     <text>
                        <paragraph>Sufentanil may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control during Sufentanil Citrate Injection therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.12">
                     <id root="02974f12-bffa-4e1c-a538-7a2b5d018e88"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Risks of Driving and Operating Machinery</title>
                     <text>
                        <paragraph>Sufentanil Citrate Injection may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of Sufentanil Citrate Injection and know how they will react to the medication.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="8fc41900-3ed9-412d-85d0-389bf8bad759"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are described, or described in greater detail, in other sections:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Addiction, Abuse, and Misuse <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Life-Threatening Respiratory Depression <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Skeletal Muscle Rigidity and Skeletal Muscle Movement <content styleCode="italics">[see </content>
                        <content styleCode="italics">
                           <linkHtml href="#S5.4">Warnings and Precautions (5.5)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>
                        <caption>•</caption>Interactions with Benzodiazepines or Other CNS Depressants <content styleCode="italics">[see <linkHtml href="#ID_6ba564bf-915e-4370-a8fa-52b7dec44b36">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Severe Cardiovascular Depression <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Opioid-Induced Hyperalgesia and Allodynia<content styleCode="italics"> [see <linkHtml href="#ID_2023a8f1-4f67-4fe0-974f-1f2a311e5855">Warnings and Precautions (5.7)</linkHtml>]‎</content>
                     </item>
                     <item>
                        <caption>•</caption>Serotonin Syndrome <content styleCode="italics">[see </content>
                        <content styleCode="italics">
                           <linkHtml href="#S5.7">Warnings and Precautions (5.8)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>
                        <caption>•</caption>Gastrointestinal Adverse Reactions <content styleCode="italics">[see </content>
                        <content styleCode="italics">
                           <linkHtml href="#S5.10">Warnings and Precautions (5.11)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>
                        <caption>•</caption>‎ Seizures <content styleCode="italics">[see </content>
                        <content styleCode="italics">
                           <linkHtml href="#S5.11">Warnings and Precautions (5.12)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions were apnea, rigidity, and bradycardia. (<linkHtml href="#S6">6</linkHtml>)<br/>
                           <br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100 or FDA at 1-800-FDA-1088 or <content styleCode="italics">
                                 <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                              </content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="3a014380-9642-40f5-83ab-ade840712c52"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                     <component>
                        <section ID="ID_a234a419-c4f6-4b83-bf65-3f6219c465c7">
                           <id root="f2af3213-b209-46be-ba1b-d2d5def3b83b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Epidural Use in Labor and Delivery</content>
                              </paragraph>
                              <paragraph>Epidural sufentanil was tested in 340 patients in two (one single-center and one multicenter) double-blind, parallel studies. Doses ranged from 10 to 15 mcg sufentanil and were delivered in a 10 mL volume of 0.125% bupivacaine with and without epinephrine 1:200,000. In all cases sufentanil was administered following a dose of local anesthetic to test proper catheter placement. Since epidural opioids and local anesthetics potentiate each other, these results may not reflect the dose or efficacy of epidural sufentanil by itself.</paragraph>
                              <paragraph>Individual doses of 10 to 15 mcg sufentanil plus bupivacaine 0.125% with epinephrine provided analgesia during the first stage of labor with a duration of 1 to 2 hours. Onset was rapid (within 10 minutes). Subsequent doses (equal dose) tended to have shorter duration. Analgesia was profound (complete pain relief) in 80% to 100% of patients and a 25% incidence of pruritus was observed. The duration of initial doses of sufentanil plus bupivacaine with epinephrine is approximately 95 minutes, and of subsequent doses, 70 minutes.</paragraph>
                              <paragraph>There are insufficient data to critically evaluate neonatal neuromuscular and adaptive capacity following recommended doses of maternally administered epidural sufentanil with bupivacaine. However, if larger than recommended doses are used for combined local and systemic analgesia, e.g., after administration of a single dose of 50 mcg epidural sufentanil during delivery, then impaired neonatal adaption to sound and light can be detected for 1 to 4 hours and if a dose of 80 mcg is used impaired neuromuscular coordination can be detected for more than 4 hours.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="3261b6ac-2e00-4ac4-90ac-ab188afad38a"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of sufentanil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                     <component>
                        <section ID="ID_0de0075e-4564-4557-b377-3f0a295dab3f">
                           <id root="91d79687-0f8a-448e-bd21-43f83efd0bf0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Serotonin syndrome</content>: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of opioids with serotonergic drugs.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_7d515d23-8a88-4150-b32b-7e24220cb21c">
                           <id root="b695c50a-ca3b-4278-a315-09e277f6a77d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adrenal insufficiency</content>: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_09c1b6da-3ac3-40f3-afdf-d662e47d641d">
                           <id root="df812700-f715-4367-b318-f708e17db437"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Anaphylaxis</content>: Anaphylaxis has been reported with ingredients contained in Sufentanil Citrate Injection.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_872e9a59-3fda-4a5b-90de-62db303a9cbd">
                           <id root="1bea37a8-bff8-4399-9a57-91389a05728b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Androgen deficiency</content>: Cases of androgen deficiency have occurred with use of opioids for an extended period of time <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Hyperalgesia and Allodynia</content>: Cases of hyperalgesia and allodynia have been ‎reported with opioid therapy of any duration <content styleCode="italics">[see <linkHtml href="#ID_2023a8f1-4f67-4fe0-974f-1f2a311e5855">Warnings and Precautions ‎‎(5.7)</linkHtml>]‎</content>.</paragraph>
                              <paragraph>
                                 <content styleCode="underline">Hypoglycemia</content>: Cases of hypoglycemia have been reported in patients ‎taking opioids. Most reports were in patients with at least one ‎predisposing risk factor (e.g., diabetes).‎</paragraph>
                           </text>
                           <effectiveTime value="20231026"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="7da5205e-f7f4-417c-bded-7499e5d2fa4c"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Table 3 includes clinically significant drug interactions with Sufentanil Citrate Injection.</paragraph>
                  <table ID="_RefID0EHYAE" width="100%">
                     <caption>Table 3: Clinically Significant Drug Interactions with Sufentanil Citrate Injection</caption>
                     <col width="30%"/>
                     <col width="70%"/>
                     <tbody>
                        <tr>
                           <td colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Inhibitors of CYP3A4 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>The concomitant use of Sufentanil Citrate Injection and CYP3A4 inhibitors can increase the plasma concentration of sufentanil, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of Sufentanil Citrate Injection is achieved <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.4)</linkHtml>]</content>.<br/>
                                 <br/>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the sufentanil plasma concentration will decrease <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to sufentanil.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Intervention:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>If concomitant use is necessary, consider dosage reduction of Sufentanil Citrate Injection until stable drug effects are achieved. Monitor patients at frequent intervals for respiratory depression and sedation.<br/>
                                 <br/>If a CYP3A4 inhibitor is discontinued, consider increasing the Sufentanil Citrate Injection dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Examples:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir), grapefruit juice.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">CYP3A4 Inducers</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>The concomitant use of Sufentanil Citrate Injection and CYP3A4 inducers can decrease the plasma concentration of sufentanil <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to sufentanil <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.4)</linkHtml>]</content>.<br/>
                                 <br/>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the sufentanil plasma concentration will increase <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>, which could increase or prolong both the therapeutic effects and adverse reactions and may cause serious respiratory depression.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Intervention:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>If concomitant use is necessary, consider increasing the Sufentanil Citrate Injection dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider Sufentanil Citrate Injection dosage reduction and monitor for signs of respiratory depression.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Examples:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Rifampin, carbamazepine, phenytoin</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>The concomitant use of Sufentanil Citrate Injection with CNS depressants my result in decreased pulmonary artery pressure and may cause hypotension. Even small dosages of diazepam may cause cardiovascular depression when added to high dose or anesthetic dosages of Sufentanil Citrate Injection. As postoperative analgesia, concomitant use of Sufentanil Citrate Injection can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#ID_6ba564bf-915e-4370-a8fa-52b7dec44b36">5.3</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Intervention:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>As postoperative analgesia, start with a lower dose of Sufentanil Citrate Injection and monitor patients for signs of respiratory depression, sedation, and hypotension. Fluids or other measures to counter hypotension should be available <content styleCode="italics">[see </content>
                                 <content styleCode="italics">
                                    <linkHtml href="#ID_6ba564bf-915e-4370-a8fa-52b7dec44b36">Warnings and Precautions (5.3)</linkHtml>
                                 </content>
                                 <content styleCode="italics">]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Examples:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Serotonergic Drugs</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome <content styleCode="italics">[see </content>
                                 <content styleCode="italics">
                                    <linkHtml href="#S5.7">Warnings and Precautions (5.8)</linkHtml>
                                 </content>
                                 <content styleCode="italics">].</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Intervention:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue Sufentanil Citrate Injection if serotonin syndrome is suspected.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Examples:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5‑HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma) <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Intervention:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>The use of Sufentanil Citrate Injection is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Examples:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>phenelzine, tranylcypromine, linezolid</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>May reduce the analgesic effect of Sufentanil Citrate Injection and/or precipitate withdrawal symptoms.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Intervention:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Avoid concomitant use.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Examples:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>butorphanol, nalbuphine, pentazocine, buprenorphine</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Muscle Relaxants</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Sufentanil may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Intervention:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of Sufentanil Citrate Injection and/or the muscle relaxant as necessary.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Diuretics</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Intervention:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Anticholinergic Drugs</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Intervention:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Monitor patients for signs of urinary retention or reduced gastric motility when Sufentanil Citrate Injection is used concomitantly with anticholinergic drugs.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Nitrous oxide</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Nitrous oxide has been reported to produce cardiovascular depression when given with higher doses of Sufentanil Citrate Injection.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">
                                    <content styleCode="italics">Intervention:</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Monitor patients for signs of cardiovascular depression that may be greater than otherwise expected.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Concomitant Use of CNS Depressants</content>: May decrease pulmonary arterial pressure and may cause hypotension. See FPI for management instructions. For post-operative pain, start with the lowest effective dosage and monitor for potentiation of CNS depressant effects. (<linkHtml href="#ID_6ba564bf-915e-4370-a8fa-52b7dec44b36">5.3</linkHtml>, <linkHtml href="#S7">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>: Avoid use with Sufentanil Citrate Injection because they may reduce analgesic effect of Sufentanil Citrate Injection or precipitate withdrawal symptoms. (<linkHtml href="#S7">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="95d6c5aa-2f04-44f5-90d5-1725e4fbc16b"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Pregnancy</content>: May cause fetal harm. (<linkHtml href="#S8.1">8.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Lactation</content>: Infants exposed to Sufentanil Citrate Injection through breast milk should be monitored for excess sedation and respiratory depression. (<linkHtml href="#S8.2">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="ec204ffa-8f53-4009-8da1-088b7072adba"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250101"/>
                     <component>
                        <section ID="ID_56f35284-922e-4c83-badc-fc83349ab047">
                           <id root="a6e7759f-31c6-4792-a16f-918b5b2d584d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Use of opioid analgesics for an extended period of time during pregnancy may cause neonatal opioid withdrawal syndrome. Available data with Sufentanil Citrate Injection in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage.</paragraph>
                              <paragraph>In animal reproduction studies, embryolethality and maternal toxicity were noted in rabbits when sufentanil was administered intravenously at 0.9 times the human procedural dose of 30 mcg/kg during organogenesis. Decreased live fetuses and pup survival were noted in rats treated with sufentanil late in gestation and throughout lactation at doses below the human procedural dose. No malformations were observed in either rats or rabbits at doses below the human procedural dose <content styleCode="italics">[see <linkHtml href="#Data">Data</linkHtml>].</content>
                              </paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20231218"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_b42ad32e-8613-4db6-a28d-e715418b4397">
                           <id root="37264410-24c2-4fd4-b77e-ea5f773c49a1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250101"/>
                           <component>
                              <section ID="ID_3c830484-8e1e-4c01-90c2-384a714e2990">
                                 <id root="55e6ba9a-261b-4591-8267-2136fcdd8d8e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>Use of opioid analgesics for an extended period of time during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth.</paragraph>
                                    <paragraph>Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly <content styleCode="italics">[see </content>
                                       <content styleCode="italics">
                                          <linkHtml href="#S5.3">Warnings and Precautions (5.4)</linkHtml>
                                       </content>
                                       <content styleCode="italics">]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20230918"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_2aa13a60-5880-4d27-bac5-a0d1271ca6e7">
                                 <id root="5a46f4e2-3bd8-46dc-acbd-2d30c30072af"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Labor or Delivery</content>
                                    </paragraph>
                                    <paragraph>Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. Sufentanil Citrate Injection is not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. Opioid analgesics, including Sufentanil Citrate Injection, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression.</paragraph>
                                    <paragraph>The use of epidurally administered sufentanil in combination with bupivacaine 0.125% with or without epinephrine is indicated for labor and delivery. Sufentanil is not recommended for intravenous use or for use of larger epidural doses during labor and delivery because of potential risks to the newborn infant after delivery. In clinical trials, one case of severe fetal bradycardia associated with maternal hypotension was reported within 8 minutes of maternal administration of sufentanil 15 mcg plus bupivacaine 0.125% (10 mL total volume).</paragraph>
                                 </text>
                                 <effectiveTime value="20250101"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="a0d1f30b-1062-4412-9444-51f43f620be1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250101"/>
                           <component>
                              <section ID="ID_47f5c8df-54a3-476d-946b-948acf0605e3">
                                 <id root="7aed0aca-13e4-4132-af98-f22110287d89"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Pregnant rats were treated with intravenous sufentanil doses of 0.005, 0.02, or 0.08 mg/kg/day (0.03, 0.1, or 0.4 times the human total procedural dose of 30 mcg/kg based on body surface area, respectively). No malformations or embryotoxic effects were noted despite maternal toxicity (increased mortality in the mid- and high-dose group).</paragraph>
                                    <paragraph>Pregnant rabbits were treated with intravenous sufentanil doses of 0.005, 0.02, or 0.08 mg/kg/day (0.05, 0.2, or 0.9 times the human total procedural dose of 30 mcg/kg based on body surface area, respectively). Decreased live fetuses per litter and decreased litter size in the high dose group were noted in the presence of maternal toxicity (decreased body weight gain and mortality in the high-dose group).</paragraph>
                                    <paragraph>No evidence of malformations or adverse effects on the fetus was reported in a published study in which pregnant rats were administered 10, 50, or 100 mcg/kg/day sufentanil (0.05, 0.27, or 0.54 times the human procedural dose of 30 mcg/kg/day based on body surface area) continuously from Gestation Day 5 through Gestation Day 20 via subcutaneously implanted osmotic minipumps.</paragraph>
                                    <paragraph>Pregnant rats were treated intravenously with sufentanil 0.005, 0.02, or 0.08 mg/kg/day (0.03, 0.1, or 0.4 times the human total procedural dose of 30 mcg/day based on body surface area, respectively) from Gestation Day 16 through Lactation Day 21. Sufentanil reduced birth weights in the mid- and high-dose groups, decreased live fetuses in the high-dose group, and decreased pup survival in all groups in the presence of maternal toxicity (decreased weight gain and increased mortality in all groups).</paragraph>
                                 </text>
                                 <effectiveTime value="20250101"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="9073a422-1869-470e-8056-e62a0df7a9e7"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250101"/>
                     <component>
                        <section ID="ID_d6b2cc84-be1c-4916-97ab-1b1cd0370ac7">
                           <id root="423baf52-a904-4638-81b8-f7ca65a2598e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Sufentanil Citrate Injection and any potential adverse effects on the breastfed infant from Sufentanil Citrate Injection or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_c0b03df7-bb54-4145-bd32-896c01256012">
                           <id root="6bf5e55d-9f70-4063-a0e0-e71eda70adf2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                              <paragraph>Monitor infants exposed to Sufentanil Citrate Injection through breast milk for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal administration of an opioid analgesic is stopped, or when breastfeeding is stopped.</paragraph>
                           </text>
                           <effectiveTime value="20231218"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="1f39b2a7-cf81-47b2-b77e-138ba2336f77"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20250101"/>
                     <component>
                        <section ID="ID_7b58e102-700e-4ebb-8c03-91c01195d6b9">
                           <id root="5fef2b8c-9492-4fcc-aee3-facd8e5074c7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infertility</content>
                              </paragraph>
                              <paragraph>Use of opioids for an extended period of time may cause reduced fertility in females and males of reproductive potential. It is not known whether these effects on fertility are reversible <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="79ecaaed-9ef1-45d6-b480-f2f6d44c25df"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and efficacy of intravenous sufentanil in pediatric patients as young as 1 day old undergoing cardiovascular surgery have been documented in a limited number of cases. The clearance of sufentanil in healthy neonates is approximately one-half that in adults and children. The clearance rate of sufentanil can be further reduced by up to a third in neonates with cardiovascular disease, resulting in an increase in the elimination half-life of the drug.</paragraph>
                     </text>
                     <effectiveTime value="20230717"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="76e15995-d9e7-44c8-9909-80aafe99144a"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Elderly patients (aged 65 years or older) may have increased sensitivity to sufentanil. In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of Sufentanil Citrate Injection slowly in geriatric patients and monitor closely for signs of central nervous system and respiratory depression <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231218"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="d8e9aa5e-e78a-4540-b285-feb69dafb470"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>Sufentanil Citrate Injection should be administered with caution to patients with liver dysfunction because of the extensive hepatic metabolism. Reduce the dosage as needed and monitor closely for signs of respiratory depression, sedation, and hypotension.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="87499db3-34f1-4173-97bd-2d9efb14388e"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph>Sufentanil Citrate Injection should be administered with caution to patients with kidney dysfunction because of the renal excretion of sufentanil citrate and its metabolites. Reduce the dosage as needed and monitor for signs of respiratory depression, sedation, and hypotension.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S9">
               <id root="84ad4919-d506-4191-a511-30b285882d1a"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20250101"/>
               <component>
                  <section ID="S9.1">
                     <id root="03f1ea9d-e830-4c29-bb0b-6f46dccf57f2"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>Sufentanil Citrate Injection contains sufentanil, a Schedule II controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20230717"/>
                  </section>
               </component>
               <component>
                  <section ID="S9.2">
                     <id root="4d286e90-77f1-4d7f-8688-80b6a71d98b6"/>
                     <code code="34086-9" codeSystem="2.16.840.1.113883.6.1" displayName="ABUSE SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Sufentanil Citrate Injection contains sufentanil, a substance with high potential for misuse and abuse, which can lead to the development of substance use disorder, including addiction <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and ‎Precautions (5.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Misuse is the intentional use, for therapeutic purposes, of a drug by an ‎individual in a way other than prescribed by a healthcare provider or for ‎whom it was not prescribed.‎</paragraph>
                        <paragraph>Abuse is the intentional, non-therapeutic use of a drug, even once, for its ‎desirable psychological or physiological effects.‎</paragraph>
                        <paragraph>Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use ‎(e.g., continuing drug use despite harmful consequences, giving a higher ‎priority to drug use than other activities and obligations), and possible ‎tolerance or physical dependence.‎</paragraph>
                        <paragraph>Misuse and abuse of Sufentanil Citrate Injection increases risk of ‎overdose, which may lead to central nervous system and respiratory ‎depression, hypotension, seizures, and death. The risk is increased with ‎concurrent abuse of Sufentanil Citrate Injection with alcohol and/or other ‎CNS depressants. Abuse of and addiction to opioids in ‎some individuals may not be accompanied by concurrent tolerance and ‎symptoms of physical dependence. In addition, abuse of opioids can occur ‎in the absence of addiction.‎</paragraph>
                        <paragraph>All patients treated with opioids require careful and frequent reevaluation ‎for signs of misuse, abuse, and addiction, because use of opioid analgesic ‎products carries the risk of addiction even under appropriate medical use. ‎Patients at high risk of Sufentanil Citrate Injection abuse include those ‎with a history of prolonged use of any opioid, including products containing sufentanil, those ‎with a history of drug or alcohol abuse, or those who use Sufentanil ‎Citrate Injection in combination with other abused drugs.‎</paragraph>
                        <paragraph>‎“Drug-seeking” behavior is very common in persons with substance use ‎disorders. Drug-seeking tactics include emergency calls or visits near the ‎end of office hours, refusal to undergo appropriate examination, testing, or ‎referral, repeated “loss” of prescriptions, tampering with prescriptions, and ‎reluctance to provide prior medical records or contact information for other ‎treating healthcare provider(s). “Doctor shopping” (visiting multiple ‎prescribers to obtain additional prescriptions) is common among people ‎who abuse drugs and people with substance use disorder. Preoccupation ‎with achieving adequate pain relief can be appropriate behavior in a ‎patient with inadequate pain control.‎</paragraph>
                        <paragraph>Sufentanil Citrate Injection, like other opioids, can be diverted for nonmedical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by state and federal law, is strongly advised.</paragraph>
                        <paragraph>Proper assessment of the patient, proper prescribing practices, periodic re‎evaluation of therapy, and proper dispensing and storage are appropriate ‎measures that help to limit abuse of opioid drugs.‎</paragraph>
                     </text>
                     <effectiveTime value="20231218"/>
                     <component>
                        <section ID="ID_c1b69ffa-a167-4542-a9da-ab441c8909ce">
                           <id root="94bbc16d-0819-4573-9a6f-5998979c76be"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risks Specific to Abuse of Sufentanil Citrate Injection</content>
                              </paragraph>
                              <paragraph>Abuse of Sufentanil Citrate Injection poses a risk of overdose and death. The risk is increased with concurrent use of Sufentanil Citrate Injection with alcohol and/or other CNS depressants. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.</paragraph>
                           </text>
                           <effectiveTime value="20230918"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S9.3">
                     <id root="c1630d7d-2223-45bb-ad5a-589d7ee2ae26"/>
                     <code code="34087-7" codeSystem="2.16.840.1.113883.6.1" displayName="DEPENDENCE SECTION"/>
                     <title>9.3 Dependence</title>
                     <text>
                        <paragraph>Both tolerance and physical dependence can develop during use of opioid therapy.</paragraph>
                        <paragraph>Tolerance is a physiological state characterized by a reduced response to a drug after ‎repeated administration (i.e., a higher dose of a drug is required to ‎produce the same effect that was once obtained at a lower dose).‎</paragraph>
                        <paragraph>Physical dependence is a state that develops as a result of a physiological adaptation in ‎response to repeated drug use, manifested by withdrawal signs and ‎symptoms after abrupt discontinuation or a significant dose reduction of a ‎drug.‎ </paragraph>
                        <paragraph>Withdrawal may be precipitated through the administration of drugs with opioid antagonist activity (e.g., naloxone), mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol, nalbuphine), or partial agonists (e.g., buprenorphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued use.</paragraph>
                        <paragraph>Sufentanil Citrate Injection should not be abruptly discontinued in a ‎physically-dependent patient. If Sufentanil Citrate Injection is abruptly ‎discontinued in a physically-dependent patient, a withdrawal syndrome ‎may occur, typically characterized by restlessness, lacrimation, rhinorrhea, ‎perspiration, chills, myalgia, and mydriasis. Other signs and symptoms ‎also may develop, including irritability, anxiety, backache, joint pain, ‎weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, ‎diarrhea, or increased blood pressure, respiratory rate, or heart rate.‎</paragraph>
                        <paragraph>Infants born to mothers physically-dependent on opioids will also be ‎physically-dependent and may exhibit respiratory difficulties and ‎withdrawal signs <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.‎</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="d0f36eda-9cfa-4908-851c-5c622d332053"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <effectiveTime value="20231218"/>
               <component>
                  <section ID="ID_0f28ca8c-9b4b-49fb-a70e-4445ec526c91">
                     <id root="32401b44-9bcc-405e-8123-073871ce1eef"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Clinical Presentation</content>
                        </paragraph>
                        <paragraph>Acute overdose with sufentanil can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, hypoglycemia, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen with hypoxia in overdose situations <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231218"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f85883d5-d5c9-4055-8d04-4fd061f6e21c">
                     <id root="a4fb008a-f39f-4940-b493-66eaba8fff81"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Treatment of Overdose</content>
                        </paragraph>
                        <paragraph>In case of overdose, priorities are the reestablishment of a patent and protected airway and institution of assisted or controlled ventilation, if needed. Employ other supportive measures (including oxygen and vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life-support measures. </paragraph>
                        <paragraph>Opioid antagonists, such as naloxone, are specific antidotes to respiratory depression resulting from opioid overdose. For clinically significant respiratory or circulatory depression secondary to sufentanil overdose, administer an opioid antagonist. </paragraph>
                        <paragraph>Because the duration of opioid reversal is expected to be less than the duration of action of sufentanil in Sufentanil Citrate Injection, carefully monitor the patient until spontaneous respiration is reliably reestablished. If the response to an opioid antagonist is suboptimal or only brief in nature, administer additional antagonist as directed by the product's prescribing information. </paragraph>
                        <paragraph>In an individual physically-dependent on opioids, administration of the recommended usual dosage of the antagonist will precipitate an acute withdrawal syndrome. The severity of the withdrawal symptoms experienced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically-dependent patient, administration of the antagonist should be initiated with care and by titration with smaller than usual doses of the antagonist.</paragraph>
                     </text>
                     <effectiveTime value="20231218"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="6e1033c1-3671-4be1-abf9-8ed85b26855c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Sufentanil Citrate Injection, USP is a sterile, nonpyrogenic solution of sufentanil citrate in water for injection. Sufentanil Citrate is a potent opioid analgesic which is administered either epidurally or by intravenous injection.</paragraph>
                  <paragraph>Each mL contains sufentanil citrate equivalent to 50 mcg of sufentanil. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. pH 4.2 (3.5 to 6.0).</paragraph>
                  <paragraph>The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended for use only as a single-use injection. When smaller doses are required, the unused portion should be discarded in an appropriate manner.</paragraph>
                  <paragraph>Sufentanil Citrate, USP, occurs as a white crystalline powder and is chemically designated as <content styleCode="italics">N</content>-[-4-(methyoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-<content styleCode="italics">N</content>-phenylpropanamide 2-hydroxy-1,2,3-propanetricarboxylate (1:1).</paragraph>
                  <paragraph>The molecular formula of sufentanil citrate is C<sub>22</sub>H<sub>30</sub>N<sub>2</sub>O<sub>2</sub>S∙C<sub>6</sub>H<sub>8</sub>O<sub>7</sub> and the molecular weight is 578.69. Sufentanil Citrate has the following structural formula:</paragraph>
                  <renderMultiMedia ID="id1345" referencedObject="MM1"/>
               </text>
               <effectiveTime value="20230717"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="sufentanil-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="9c8c485a-a777-43ee-afdd-4b0fe01dbef7"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250101"/>
               <component>
                  <section ID="S12.1">
                     <id root="b590bd9a-1b1d-47d1-989d-756958d71b25"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Sufentanil is an opioid agonist. When used in balanced general anesthesia, sufentanil has been reported to be as much as 10 times as potent as fentanyl. When administered intravenously as a primary anesthetic agent with 100% oxygen, sufentanil is approximately 5 to 7 times as potent as fentanyl.</paragraph>
                     </text>
                     <effectiveTime value="20250101"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="acc205f7-016f-459f-84fa-cdddb14745e6"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20231218"/>
                     <component>
                        <section ID="ID_93013de5-4a3a-4dfc-b6d1-714d8916c7b1">
                           <id root="e2b35974-d143-41a2-b128-e8743dd317b0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Central Nervous System</content>
                              </paragraph>
                              <paragraph>Sufentanil produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves both a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation.</paragraph>
                              <paragraph>Sufentanil causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origins may produce similar findings). Marked mydriasis rather than miosis may be seen due to hypoxia in overdose situations.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_38d3dec5-6f2e-4637-9eed-9500d395c275">
                           <id root="503bfcd0-4742-490c-a4b8-38250901daa7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Gastrointestinal Tract and Other Smooth Muscle</content>
                              </paragraph>
                              <paragraph>Sufentanil causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in biliary and pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum amylase.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_507077f1-909d-470b-8162-9cc1ff52266c">
                           <id root="0cf8a6fa-3fed-460e-8697-eb882eb5dfdf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Cardiovascular System</content>
                              </paragraph>
                              <paragraph>Sufentanil produces peripheral vasodilation which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes and sweating and/or orthostatic hypotension.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_58f81217-f958-432c-b2b4-9b8514a4e3af">
                           <id root="e05fc8c7-dc04-46ae-a8da-78a459bdf61c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Endocrine System</content>
                              </paragraph>
                              <paragraph>Opioids inhibit the secretion of adrenocorticotropic hormone (ACTH), cortisol, and luteinizing hormone (LH) in humans. They also stimulate prolactin, growth hormone (GH) secretion, and pancreatic secretion of insulin and glucagon <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
                              <paragraph>Use of opioids for an extended period of time may influence the hypothalamic-pituitary-gonadal axis, leading to androgen deficiency that may manifest as low libido, impotence, erectile dysfunction, amenorrhea, or infertility. The causal role of opioids in the clinical syndrome of hypogonadism is unknown because the various medical, physical, lifestyle, and psychological stressors that may influence gonadal hormone levels have not been adequately controlled for in studies conducted to date <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_eb1cf111-e308-4642-b5df-2e79080b82f7">
                           <id root="3e5b9518-c66e-4ab7-aaee-9705a854af28"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Effects on the Immune System</content>
                              </paragraph>
                              <paragraph>Opioids have been shown to have a variety of effects on components of the immune system in <content styleCode="italics">in vitro</content> and animal models. The clinical significance of these findings is unknown. Overall, the effects of opioids appear to be modestly immunosuppressive.</paragraph>
                           </text>
                           <effectiveTime value="20231218"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_5d947aa3-0382-4250-a2d8-5fdb46e4f7b4">
                           <id root="7677d47d-eac2-4243-ad1c-a98f12f8a424"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Concentration–Efficacy Relationships</content>
                              </paragraph>
                              <paragraph>The minimum effective analgesic concentration will vary widely among patients, especially among patients who have been previously treated with opioid agonists <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#S2.2">2.2)</linkHtml>]</content>. The minimum effective analgesic concentration of sufentanil for any individual patient may increase over time due to an increase in pain, the development of a new pain syndrome and/or the development of analgesic tolerance.</paragraph>
                           </text>
                           <effectiveTime value="20231218"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_1225cff2-abcd-4801-81a1-bbb8fc3ac476">
                           <id root="64438485-f76e-4ce8-a40d-86fa43601ce5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Concentration–Adverse Reaction Relationships</content>
                              </paragraph>
                              <paragraph>There is a relationship between increasing sufentanil plasma concentration and increasing frequency of dose-related opioid adverse reactions such as nausea, vomiting, CNS effects, and respiratory depression. In opioid-tolerant patients, the situation may be altered by the development of tolerance to opioid-related adverse reactions <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.3">2.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="957caefb-f948-4427-ae45-4c0268842c98"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Sufentanil Citrate Injection is administered by the intravenous or epidural route. The pharmacokinetics of intravenous sufentanil can be described as a three-compartment model.</paragraph>
                     </text>
                     <effectiveTime value="20231218"/>
                     <component>
                        <section ID="ID_fa972e92-28c8-4e3c-9c16-e3c6111040e8">
                           <id root="ac57b91a-7167-4a45-b506-3f8a665da644"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>After epidural administration of incremental doses totaling 5 to 40 mcg sufentanil during labor and delivery, maternal and neonatal sufentanil plasma concentrations were at or near the 0.05 to 0.1 ng/mL limit of detection, and were slightly higher in mothers than in their infants.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_40f73340-c5ce-4126-83aa-daa0636b9cea">
                           <id root="bb6b97cc-11a0-420b-a56a-92dbae88784d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Plasma protein binding of sufentanil, related to the alpha acid glycoprotein concentration, was approximately 93% in healthy males, 91% in mothers and 79% in neonates. Sufentanil has a distribution time of 1.4 minutes and redistribution time of 17.1 minutes.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_3596ecb9-0c55-4785-9f18-8fcd86927dec">
                           <id root="e6ee0365-37a5-4227-8de2-9c5540e4fbac"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The elimination half-life is 164 minutes in adults. The elimination half-life of sufentanil is shorter (e.g., 97 +/- 42 minutes) in infants and children, and longer in neonates (e.g., 434 +/- 160 minutes) compared to that of adolescents and adults.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_76e0c944-21d0-48f0-8cff-003dd05d06c3">
                           <id root="2a707e57-bffc-42a9-b6fb-5a602f0f632b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Metabolism</content>
                              </paragraph>
                              <paragraph>The liver and small intestine are the major sites of biotransformation.</paragraph>
                           </text>
                           <effectiveTime value="20231218"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_c0214abe-d963-4540-a795-473e70a8bd72">
                           <id root="f0e238be-d446-4208-8a60-6b391dbdbbce"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Excretion</content>
                              </paragraph>
                              <paragraph>Approximately 80% of the administered dose is excreted within 24 hours and only 2% of the dose is eliminated as unchanged drug.</paragraph>
                           </text>
                           <effectiveTime value="20231218"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="454b00ef-79ea-4d44-a3ad-4350b6476418"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250101"/>
               <component>
                  <section ID="S13.1">
                     <id root="d28ab8eb-b0d2-4d71-9b40-d5d85781317d"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250101"/>
                     <component>
                        <section ID="ID_bf05ff86-455c-45d3-b71f-6bcbfdea1011">
                           <id root="48634b13-f277-486e-981b-9c34153d4229"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Long-term studies in animals to evaluate the carcinogenic potential of sufentanil have not been conducted.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_23f1f59d-8b06-42c8-8154-9b785e774784">
                           <id root="7c3ad3cb-da67-4a98-9213-228ec00c4400"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Sufentanil was not genotoxic in the <content styleCode="italics">in vitro</content> bacterial reverse mutation assay (Ames assay) or in the <content styleCode="italics">in vivo</content> rat bone marrow micronucleous assay.</paragraph>
                           </text>
                           <effectiveTime value="20231218"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_85faa434-a9ae-4edf-a393-baccf7a66839">
                           <id root="781f3b07-7bf0-4091-a2d5-a92e75ad969c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Fertility and early embryonic development studies were conducted in male and female rats treated with 0.005, 0.02 or 0.08 mg/kg sufentanil IV for 56 days and 14 days prior to mating through gestation respectively. Increased mortality was noted in all treatment groups. Lower pregnancy rated were noted following treatment of males at doses of 0.02 and 0.08 mg/kg (0.1 and 0.4 times the maximum human total procedural dose of 30 mcg/kg IV, based on a body surface area comparison), suggesting the potential for an adverse effect on fertility in males. Increased resorption of fetuses and reduced litter size was noted in the high dose females (0.4 times the maximum human total procedural dose of 30 mcg/kg IV, based on a body surface area comparison) suggesting the potential for fetotoxicity, likely due to maternal toxicity.</paragraph>
                           </text>
                           <effectiveTime value="20230717"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="5913b4e0-64a5-48d2-9d86-4096582413eb"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20230717"/>
               <component>
                  <section ID="ID_67ab429e-12f6-43ff-b39d-d45ee028cb90">
                     <id root="500c3b8b-564e-4938-8abf-0371be40e0cb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Epidural Use in Labor and Delivery</content>
                        </paragraph>
                        <paragraph>Epidural sufentanil was tested in 340 patients in two (one single-center and one multicenter) double-blind, parallel studies. Doses ranged from 10 to 15 mcg sufentanil and were delivered in a 10 mL volume of 0.125% bupivacaine with and without epinephrine 1:200,000. In all cases sufentanil was administered following a dose of local anesthetic to test proper catheter placement. Since epidural opioids and local anesthetics potentiate each other, these results may not reflect the dose or efficacy of epidural sufentanil by itself.</paragraph>
                        <paragraph>Individual doses of 10 to 15 mcg sufentanil plus bupivacaine 0.125% with epinephrine provided analgesia during the first stage of labor with a duration of 1 to 2 hours. Onset was rapid (within 10 minutes). Subsequent doses (equal dose) tended to have shorter duration. Analgesia was profound (complete pain relief) in 80% to 100% of patients and a 25% incidence of pruritus was observed. The duration of initial doses of sufentanil plus bupivacaine with epinephrine is approximately 95 minutes, and of subsequent doses, 70 minutes.</paragraph>
                        <paragraph>There are insufficient data to critically evaluate neonatal neuromuscular and adaptive capacity following recommended doses of maternally administered epidural sufentanil with bupivacaine. However, if larger than recommended doses are used for combined local and systemic analgesia, e.g., after administration of a single dose of 50 mcg epidural sufentanil during delivery, then impaired neonatal adaption to sound and light can be detected for 1 to 4 hours and if a dose of 80 mcg is used impaired neuromuscular coordination can be detected for more than 4 hours.</paragraph>
                     </text>
                     <effectiveTime value="20230717"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="481f1ab2-f4ae-4757-b8fd-cb1ad005cd2e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Sufentanil Citrate Injection, USP equivalent to 50 mcg/mL sufentanil is supplied in the following single-dose containers:</paragraph>
                  <table styleCode="Noautorules" width="80%">
                     <col width="45%"/>
                     <col width="46%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Unit of Sale</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Concentration</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">NDC 0409-3382-21</content>
                              </paragraph>
                              <paragraph>Carton of 10 Single-dose Fliptop Vials </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>50 mcg/mL</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">NDC 0409-3382-22</content>
                              </paragraph>
                              <paragraph>Carton of 10 Single-dose Fliptop Vials </paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>100 mcg/2 mL</paragraph>
                              <paragraph>(50 mcg/mL)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">NDC 0409-3382-25</content>
                              </paragraph>
                              <paragraph>Carton of 10 Single-dose Fliptop Vials </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>250 mcg/5 mL</paragraph>
                              <paragraph>(50 mcg/mL)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250101"/>
               <component>
                  <section ID="ID_ba1582c8-94c4-408e-a81a-f294d2fc6371">
                     <id root="48ee774a-4d10-4d45-86f4-cfcda725e91b"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Protect from light. Retain in carton until time of use.</paragraph>
                        <paragraph>Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.]</paragraph>
                     </text>
                     <effectiveTime value="20230717"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_F53975A0-06A2-44DF-A08C-FD38E679D11F">
               <id root="9c293408-d9ba-4e14-90cf-a185d07ffa0a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Addiction, Abuse, and Misuse</content>
                  </paragraph>
                  <paragraph>Inform patients that the use of Sufentanil Citrate Injection, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death <content styleCode="italics">[<linkHtml href="#S5.1">see Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Life-Threatening Respiratory Depression</content>
                  </paragraph>
                  <paragraph>Inform patients of the risk of life-threatening respiratory depression, including information that the risk is greatest when starting Sufentanil Citrate Injection or when the dosage is increased, and that it can occur even at recommended dosages.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hyperalgesia and Allodynia</content>
                  </paragraph>
                  <paragraph>Advise patients to inform their healthcare provider if they experience symptoms of hyperalgesia, including worsening pain, increased sensitivity to pain, or new pain <content styleCode="italics">[<linkHtml href="#ID_2023a8f1-4f67-4fe0-974f-1f2a311e5855">see Warnings and Precautions (5.7)</linkHtml>, <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Serotonin Syndrome</content>
                  </paragraph>
                  <paragraph>Inform patients that opioids could cause a rare but potentially life-threatening condition called serotonin syndrome resulting from concomitant administration of serotonergic drugs. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop after discharge from the hospital. Instruct patients to inform their healthcare provider if they are taking, or plan to take serotonergic medications <content styleCode="italics">[<linkHtml href="#S5.7">see Warnings and Precautions (5.8)</linkHtml>, <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Constipation</content>
                  </paragraph>
                  <paragraph>Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>, <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20231218"/>
            </section>
         </component>
         <component>
            <section ID="ID_0f16ef9f-588c-4309-a31b-d00e7b0664e4">
               <id root="d558f6e6-4ee0-45b5-b054-66546e72daf5"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <renderMultiMedia ID="id1628" referencedObject="MM2"/>
                  <paragraph>Distributed by Hospira, Inc., Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>LAB-1124-11.0</paragraph>
               </text>
               <effectiveTime value="20250101"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="sufentanil-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b7901624-e53e-4f3a-9dad-5eeb1127de46">
               <id root="1f96dd71-12a6-41fc-9537-3cd63064d77a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1 mL Vial Label</title>
               <text>
                  <paragraph>1 mL Single-dose<br/>NDC 0409-3382-11<br/>Preservative-Free<br/>Rx only</paragraph>
                  <paragraph>SUFENTANIL CITRATE<br/>Injection, USP</paragraph>
                  <paragraph>50 mcg/mL</paragraph>
                  <paragraph>CII</paragraph>
                  <paragraph>For Intravenous and Epidural Use.</paragraph>
                  <paragraph>Distributed by Hospira, Inc.,<br/>Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>Hospira</paragraph>
                  <renderMultiMedia ID="id1657" referencedObject="MM3"/>
               </text>
               <effectiveTime value="20230717"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 1 mL Vial Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="sufentanil-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_29fcb601-400b-4309-804d-91b7164a01a9">
               <id root="83f2591b-0c79-4792-a679-0f87097e1082"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1 mL Vial Carton</title>
               <text>
                  <paragraph>1 mL<br/>10 Single-dose Fliptop Vials<br/>Preservative-Free</paragraph>
                  <paragraph>Rx only<br/>NDC 0409-3382-21<br/>Contains 10 of NDC 0409-3382-11</paragraph>
                  <paragraph>Protect from light.<br/>Retain in carton<br/>until time of use.</paragraph>
                  <paragraph>CII</paragraph>
                  <paragraph>SUFENTANIL CITRATE Inj., USP<br/>50 mcg/mL*</paragraph>
                  <paragraph>For Intravenous and Epidural Use.</paragraph>
                  <paragraph>Distributed by Hospira, Inc., Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>Hospira</paragraph>
                  <renderMultiMedia ID="id1686" referencedObject="MM4"/>
               </text>
               <effectiveTime value="20230717"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>Principal Display Panel - 1 mL Vial Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="sufentanil-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_cc1bfd61-222c-4634-be39-8acb45ebcfdf">
               <id root="033c39bf-5d72-4937-b03d-e664744b7956"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 2 mL Vial Label</title>
               <text>
                  <paragraph>2 mL Single-dose<br/>NDC 0409-3382-12</paragraph>
                  <paragraph>Preservative-Free<br/>Rx only</paragraph>
                  <paragraph>SUFENTANIL<br/>CITRATE Inj., USP</paragraph>
                  <paragraph>CII</paragraph>
                  <paragraph>100 mcg/2 mL (50 mcg/mL)</paragraph>
                  <paragraph>For Intravenous and Epidural Use.</paragraph>
                  <paragraph>Distributed by Hospira, Inc.,<br/>Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>Hospira</paragraph>
                  <renderMultiMedia ID="id1712" referencedObject="MM5"/>
               </text>
               <effectiveTime value="20230717"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>Principal Display Panel - 2 mL Vial Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="sufentanil-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_28b1b59f-5acb-4574-b561-98caa1cb349b">
               <id root="3bfdf09a-6322-43e8-87e1-ddaa7ef593ef"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 2 mL Vial Carton</title>
               <text>
                  <paragraph>2 mL <br/>10 Single-dose<br/>Fliptop Vials<br/>Preservative-Free</paragraph>
                  <paragraph>Rx only<br/>NDC 0409-3382-22<br/>Contains 10 of NDC 0409-3382-12</paragraph>
                  <paragraph>Protect from light.<br/> Retain in carton <br/>until time of use.</paragraph>
                  <paragraph>CII</paragraph>
                  <paragraph>SUFENTANIL CITRATE Inj., USP<br/>100 mcg/2 mL (50 mcg/mL)*</paragraph>
                  <paragraph>For Intravenous and Epidural Use.</paragraph>
                  <paragraph>Distributed by Hospira, Inc., Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>Hospira</paragraph>
                  <renderMultiMedia ID="id1742" referencedObject="MM6"/>
               </text>
               <effectiveTime value="20230717"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>Principal Display Panel - 2 mL Vial Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="sufentanil-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_2fd2bd9a-0e50-4785-9c7f-8d3db6e94dde">
               <id root="788673a0-0ad2-45e1-9a88-0b5769c75610"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5 mL Vial Label</title>
               <text>
                  <paragraph>5 mL Single-dose<br/>Preservative-Free<br/>NDC 0409-3382-15</paragraph>
                  <paragraph>SUFENTANIL CITRATE<br/>Injection, USP</paragraph>
                  <paragraph>CII</paragraph>
                  <paragraph>250 mcg/5 mL<br/>(50 mcg/mL)</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>For Intravenous<br/>and Epidural<br/>Use. Protect<br/>from light.<br/>Retain in<br/>carton until<br/>time of use.</paragraph>
                  <paragraph>Distributed by<br/>Hospira, Inc., Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>Hospira</paragraph>
                  <renderMultiMedia ID="id1775" referencedObject="MM7"/>
               </text>
               <effectiveTime value="20230717"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>Principal Display Panel - 5 mL Vial Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="sufentanil-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_bea604b5-2a92-471f-b0a9-65c3ed71ca55">
               <id root="d8f618d5-6b4c-4ab0-9ff4-550b891c3cbd"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5 mL Vial Carton</title>
               <text>
                  <paragraph>5 mL<br/> 10 Single-dose Fliptop Vials<br/>Preservative-Free</paragraph>
                  <paragraph>Rx only<br/>NDC 0409-3382-25<br/>Contains 10 of NDC 0409-3382-15</paragraph>
                  <paragraph>SUFENTANIL CITRATE Inj., USP<br/>CII<br/>250 mcg/5 mL (50 mcg/mL)*</paragraph>
                  <paragraph>Protect from light. Retain in carton until time of use.<br/>For Intravenous and Epidural Use.</paragraph>
                  <paragraph>Distributed by Hospira, Inc., Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>Hospira</paragraph>
                  <renderMultiMedia ID="id1802" referencedObject="MM8"/>
               </text>
               <effectiveTime value="20230717"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>Principal Display Panel - 5 mL Vial Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="sufentanil-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>